Question 1

Is ipamorelin peptide safe?

Accepted Answer

The record cannot settle that, and the reason is size rather than any warning sign. One controlled trial gave ipamorelin to sick adults for up to a week in hospital, and one earlier study gave single infusions to healthy men and measured their hormones. The trial is the part worth reading closely. It was designed so that safety was assessed by monitoring adverse events and laboratory tests. Its participants were patients, since the patients were adults undergoing small and large bowel resection by open or laparoscopic surgery. Whatever that trial found about harm, it found it in that setting. Reviews that look across the whole family land on caution. A 2026 scoping review notes that these compounds are often perceived as low risk, despite the absence of efficacy or safety data for many emerging peptides. Perceived as low risk is a description of how people feel about them, which is different from a finding. A week of hospital data is a starting point for a safety record rather than the record itself.

Question 2

What side effects did the ipamorelin trial record?

Accepted Answer

Almost everyone in it had something, in both arms. The trial reports that overall incidence of any treatment-emergent adverse events was 87.5 % in the ipamorelin group and 94.8 % in placebo group. A treatment-emergent event is anything new or worse after the first dose, whatever its cause. Those high figures reflect the setting rather than the compound, because people recovering from bowel surgery develop plenty of new symptoms whether or not they receive anything, and the placebo arm displays exactly that background. The groups started out comparable, as demographic and disease characteristics were balanced between groups. What the summary omits is the list itself, since it does not name the events, count the serious ones or say whether investigators judged any of them related to ipamorelin. The useful reading is therefore narrow: in this setting, the rate of trouble on ipamorelin was not higher than the rate on placebo. That does not tell a healthy person which side effects to expect, because no study among the research behind this page has recorded side effects in one.

Question 3

How long does the human safety record for ipamorelin run?

Accepted Answer

Seven days at the longest, and fifteen minutes at the shortest. The 2014 trial gave intravenous infusions of 0.03-mg/kg ipamorelin vs placebo twice daily, on postoperative day 1 to 7 or hospital discharge, so patients discharged early would have stopped sooner. The 1999 study was briefer still. It used single infusions in eight healthy male subjects at each dose level, and its summary states that concentrations of ipamorelin and growth hormone were measured. It was a study of how the molecule moves through the body rather than of what it does to a person over time. A second phase 2 trial is registered, titled Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function, and listed as COMPLETED. Its safety findings do not appear among the research behind this page. So the published human record is one week of hospital use, which is a different question from months of use at home.

Question 4

Is it safe to take ipamorelin every day?

Accepted Answer

Daily use for weeks has not been studied in people, so there is no human finding either way. The longest daily schedule in a person ran up to a week, twice a day, by drip in a hospital bed. Animal schedules are not much longer. In one rat experiment the repeated course was a 2-day repetitive dosing regimen (four doses a day at 3-h intervals). In another, steroid-treated rats received ipamorelin daily, and after seven days the hepatic capacity of urea-N synthesis (CUNS) was determined, meaning the liver's output of urea was measured. The longest exposure on record is in fish: the administration of either 5 or 30 µg of IPA for 21 days led to a significant and dose-dependent rise in food intake in tilapia. None of those studies was built to look for harm from daily use. A 2026 review of peptides in ageing lists optimal dosing regimens among the open questions for this whole group, which is another way of saying the daily question has not been asked.

Question 5

What risks are documented for compounds like ipamorelin?

Accepted Answer

The lists exist for the whole family, rather than for ipamorelin alone. A 2026 review of peptides in sport and bodybuilding names it as one of the growth hormone secretagogues, the compounds that make the pituitary gland release more growth hormone. It then reports that emerging data highlight potential risks: cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability. Dyslipidemia means unhealthy levels of blood fats. A 2026 scoping review that covers ipamorelin by name reaches a similar list, recording that documented risks include cardiovascular complications and metabolic dysfunction such as insulin resistance. The same review flags one compound separately: some peptides such as MK-677 were associated with significant risks including congestive heart failure. That risk belongs to MK-677 rather than to ipamorelin. Read what these lists are. They gather what has been seen across a family of compounds, often in people using several of them at once, and they do not count how often any of it happens. That makes them reasons to watch for a problem, rather than measured rates for ipamorelin in particular.

Question 6

Does ipamorelin affect blood sugar?

Accepted Answer

Neither human study reported a glucose reading, so the direct answer is not known. What exists is a family-level concern and a reason it might apply. The concern is the insulin resistance named in both 2026 reviews above, which means the body needing more insulin to clear the same sugar from the blood. Those reviews describe the class rather than ipamorelin, and neither gives a number. The reason it might apply runs through what these compounds are built to do. A 2020 review of the class in men with low testosterone describes them collectively as potent GH and IGF-1 stimulators, and the hormones they raise are the ones the class-level reviews connect with insulin resistance. Yet the same review concludes that a paucity of data examining the clinical effects of these compounds currently limits our understanding of their role. So the mechanism points toward a possible effect, while no measurement among these sources has tested it in a person. For anyone managing diabetes, that gap is the finding, rather than a reassurance in either direction.

Question 7

Does ipamorelin increase appetite?

Accepted Answer

In animals, yes, and the reason is built into how it works. The same 2009 paper describes ipamorelin as a selective growth hormone secretagogue and agonist of the ghrelin receptor, ghrelin being the hunger hormone the stomach releases when it is empty. That paper opens by stating that ghrelin and ghrelin mimetics stimulate appetite and enhance gastric motility. Gastric motility is the stomach's movement. The experiments bear that out. In rats recovering from abdominal surgery, repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain in those animals. The tilapia study found a dose-dependent rise in food intake over three weeks. For rats just out of surgery, eating more was the intended outcome, whereas for a person trying to lose fat the same effect may work against them. The human trial measured time to a solid meal rather than hunger, so how much appetite rises in a person has not been measured, and a rise in a rat is a reason to expect it rather than knowledge of its size.

Question 8

Is ipamorelin hard on the liver or kidneys?

Accepted Answer

No study among the research behind this page reports a liver or kidney result in a person, so the human answer is a blank. The trial did run laboratory tests, but its summary does not report them. What the animal work shows is how the body clears ipamorelin, which tells you where it goes rather than what it does there. A 1998 rat study found that ipamorelin was mainly excreted in the urine, so the kidneys do most of the clearing. The same study adds that ipamorelin and the two NNC peptides were moderately resistant towards metabolism as 60-80% of the administered dose could be recovered from bile and urine as intact peptide. In plain terms, most of it left the rats unchanged rather than being broken down. A clearance pathway is not a harm. It does mean anyone with reduced kidney function sits outside every population studied, because no trial among these sources enrolled people on that basis, and how ipamorelin clears in such a person is unknown.

Question 9

Who should avoid taking ipamorelin?

Accepted Answer

That is a decision this page does not make for anybody, but it can show who was actually studied, which marks the boundaries of what is known. The healthy-volunteer study enrolled men only, eight to a dose level. The patient trial enrolled adults having bowel surgery, and its authors list its own weakness: this proof of concept study was small and enrolled patients with a broad range of underlying conditions. Women in good health, older adults outside hospital, teenagers, pregnant women and people with heart disease appear in no published ipamorelin study covered here. That gap matters more because use is spreading beyond the people studied. A 2026 critical review reports growing uptake among recreational gym-goers, including younger individuals, but prevalence studies are lacking. A group that was never enrolled has not been shown to be at risk, but it has not been shown to be free of risk either. The record is silent about them, which is different from being reassuring.

Question 10

What does ipamorelin interact with?

Accepted Answer

No study among the research behind this page tested ipamorelin alongside a medicine. So there is no known interaction, and also no proof that there is none, because the question has not been asked in a trial. Mixing is common enough, though. The recall record shows pharmacies putting it in one vial with a second compound, as in Ipamorelin+Sermorelin, 15mg/15mg, injection and Ipamorelin+Modified GRF 1-29, 9 mg/5mg injection. Anyone using one of those takes in two compounds at once, and no study we could find has looked at either pair for harm. The reviews name the gap but do not fill it. Among its significant knowledge gaps, a 2026 review of peptides in ageing lists the effects of combination therapy. A 2026 critical review warns that most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding. What the pairing with CJC-1295 has been measured to do is weighed separately on the CJC-1295 comparison page.

Question 11

What happens when someone stops taking ipamorelin?

Accepted Answer

On the available evidence the hormone signal ends within hours, and nothing beyond that point has been measured. The 1999 volunteer study supplies the timing, and it found that ipamorelin itself had a short terminal half-life of 2 hours, half-life being the time for half of it to clear from the blood. The growth hormone response was even more transient than the molecule, with the hormone showing an exponential decline to negligible GH concentration at all doses after each infusion. A single exposure therefore does not leave hormone levels elevated for days, in contrast with the long-acting relatives of this compound. What that study could not show is what happens after weeks of repeated use, because it administered single infusions and nothing among these sources follows anyone after a course ends. Whether the pituitary's own output dips, holds or rebounds after stopping has not been asked of ipamorelin, and a clean single pulse is a finding about one dose rather than about discontinuing a regular habit.

Question 12

Does the vial itself carry risk the compound does not?

Accepted Answer

Yes, and it is the only harm the United States record actually documents. Ten Class II recalls name ipamorelin, and the reason given is always some form of lack of assurance of sterility. One covered a single Ipamorelin 3 mg Lyophilized 1 vial, and another a batch of Ipamorelin Acetate 9 mg/9mL Injectable vials. A sterility failure is a risk carried by the needle rather than by the molecule. An injection from a batch that cannot be shown to be sterile is a problem whatever is dissolved in it, and it lands at the injection site first. The supply outside pharmacies adds a second problem. A 2026 critical review records that products are often mislabeled or contaminated, which means the compound and the amount on a label may not match the contents. A 2026 Sports Medicine review describes a parallel "gray market" of unapproved compounds operating largely outside of regulatory oversight. None of the recalls says anything about current stock, so they describe past batches rather than what is on sale today.

Question 13

Why is the ipamorelin harm record this thin?

Accepted Answer

Because its development stopped early. The clinical programme aimed at bowel recovery after surgery, and after the 2014 trial missed its efficacy goal, no later trial report appears among the research behind this page. Two registered trials, including one on Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus, were the whole of its clinical life, and ileus is the stall in bowel movement after surgery. Safety records are built by long trials in large groups, and those happen when a compound is heading for approval. Ipamorelin never got that far, so the long trials were never run. A 2026 review in Sports Medicine states the result for the whole unapproved group: rigorous human safety data are scarce, and there is potential for serious harm to patients. A 2026 review of peptides in ageing makes the long-term point directly, finding that non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. A thin record is not a clean one. It means the questions were never put, which is different from an answer of no harm.

Ipamorelin side effects and safety data